Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Friday, July 31, 2026

Snapshot: Jul 31, 2026 · 6:00 PM 100 stocks analyzed

Strong Up Day

Fri, Jul 31, 2026 Complacency High

S&P 500 surged 1.05% as VIX plummeted 14.4% on calming sentiment, but extreme single-stock dispersion—50 gainers averaging +27%, 50 losers averaging -30%—revealed a bifurcated m…

55% Broad rally with fear easing: SPY +1.05%, NASDAQ +1.59%, Russell 2000 flat as VIX crashed 14.4% into complacency territory, signaling institutional risk-appetite recovery despite underlying volatility in individual names.
30% Extreme single-stock dispersion drove the narrative: 50 gainers averaged +26.9% (max UPC +84.5%) while 50 losers averaged -29.9% (max JDZG -89.8%), with Healthcare dominating gainers at 31% but also leading losers at 33%—a stock-pickers' battlefield.
15% Clinical and dilution carnage in biotech: KPTI crashed -72.7% on Phase 3 trial failure, MBRX dumped -60.9% on dilutive offering despite trial wins, while YYAI extended a 5-day losers streak and five debutant gainers (MSGY, COPR.WT, ELOX, IESC, SCYX) signaled renewed speculative rotation into micro-caps.

Healthcare drove 31% of gainers YYAI on a 5-day losers streak 5 names returned after long absences YYAI · 5-day losers streak ZTG · 3-day gainers streak MSGY — first appearance

Market Regime

Fri, Jul 31, 2026 Neutral conf: medium macro · prototype

+22

Tailwind −100 … +100 · + tailwind / − headwind

VIX16.0 p15 Drawdown-1.6% Held2d · nascent SinceJul 30

Top drivers: VIX percentile ▲ Small-cap leadership ▼ VIX 5d momentum ▲

processId: history-market-regime

Market Indexes

Fri, Jul 31, 2026 13

S&P 500

7,489.72

+77.74

+1.05%

Dow Jones

52,485.03

+537.78

+1.04%

NASDAQ Composite

25,373.85

+398.03

+1.59%

NASDAQ 100

28,274.20

+145.86

+0.52%

DJ US Total Market

74,106.83

+682.19

+0.93%

Russell 1000

4,076.38

+40.67

+1.01%

S&P MidCap 400

3,758.64

−25.22

-0.67%

Russell 2000

2,931.34

+1.34

+0.05%

Russell 2500

1,251.44

−4.54

-0.36%

Russell 3000

4,256.18

+40.76

+0.97%

Nasdaq Financial-100

7,405.35

−35.02

-0.47%

NIFTY 50

24,383.60

+387.65

+1.62%

VIX

15.99

−2.68

-14.35%

Biggest Gainers

Fri, Jul 31, 2026 50

UPC

Universe Pharmaceuticals INCHealthcare

$3.25+$2.94

+84.5%

NASDAQ · Mkt cap $3.5 M

No news headlines were available in the last 48 hours, so the 84% gain in UPC stock cannot be directly attributed to a reported catalyst. The jump likely reflects either a delayed or after-hours announcement, technical short-covering, or market rumor not yet covered by major financial media.

The absence of any recent news headlines for a stock that gained 84% in a single day is notably unusual. For a small pharmaceutical company trading at $3.25, large single-day moves without accompanying news coverage can occur through several mechanisms. First, a significant company announcement (clinical trial result, FDA decision, partnership, or capital raise) may have been released after the Yahoo Finance RSS feed cutoff or on a venue not immediately indexed by the feed. Second, the stock may be experiencing short-squeeze pressure if it carries high short interest relative to float. Third, a rumor or social media speculation could drive retail momentum before formal news follows. Pharmaceutical stocks of this size are particularly susceptible to volatile intraday moves on speculation. Without corroborating headlines, however, determining the precise trigger remains impossible.

WETO

Webus International Limited Ordinary SharesTechnology

$0.09+$0.03

+83.3%

MSGY

Masonglory LimitedIndustrials

$0.30+$0.23

+70.5%

NASDAQ · Mkt cap $5.8 M

No news headlines were found in the last 48 hours, so the cause of the 70% gain cannot be directly attributed to a reported event. The jump is likely driven by technical factors, a delayed announcement, or market speculation in a micro-cap security.

Masonglory Limited experienced a substantial 70% single-day gain while ranking as the third biggest gainer on NASDAQ, yet no news headlines appeared in the Yahoo Finance RSS feed for the preceding 48 hours. This absence of reported catalysts is notable and suggests several possibilities. In penny stocks and micro-cap securities like those trading at $0.30, price moves of this magnitude often occur due to technical factors such as short covering, momentum trading, or low volume amplification effects. Alternatively, the catalyst could be a delayed announcement or earnings report that markets learned about through channels other than the major financial news wires covered by the RSS feed provided. Without access to company filings, press releases, or trading volume data, it is impossible to determine which mechanism drove the move.

FMFC

Kandal M Venture LimitedConsumer Cyclical

$0.52+$0.14

+63.0%

NASDAQ · Mkt cap $4.1 M

Kandal M Venture Limited announced full-year fiscal 2026 financial results and outlined plans to build a tech-enabled, multi-country manufacturing platform, likely triggering the 63% jump in this small-cap stock.

The company released earnings results for the fiscal year ended March 31, 2026, paired with a strategic announcement about expanding into a tech-enabled, multi-country manufacturing platform. For a micro-cap stock trading at $0.52, even modest positive earnings or a forward-looking operational initiative can trigger outsized percentage moves, especially if the stock had been depressed or overlooked. The headline explicitly mentions "Takes Actions to Build a Tech-Enabled, Multi-Country Manufacturing Platform," which suggests management is pursuing growth initiatives that may have resonated with investors. Without access to the full earnings detail (revenue, profit, guidance), we cannot determine if results beat expectations or merely met them, but the combination of reported results and a strategic platform-building announcement is a reasonable catalyst for a micro-cap gainer. The stock's rank as the fourth biggest gainer suggests broad intraday momentum, which may also reflect short covering or retail interest in a beaten-down small-cap name.

TCX

Tucows IncTechnology

$15.43+$5.70

+58.5%

NASDAQ · Mkt cap $114 M

No news headlines were found in the last 48 hours, so the 58.53% gain in TCX cannot be directly attributed to a disclosed event. The move likely reflects either delayed market reaction to unreported news, technical factors, or a catalyst outside the tracked news feed.

TCX (Tucows Inc.) jumped nearly 59% with no corresponding headlines in the Yahoo Finance RSS feed over the past two days. This disconnect suggests either the move was driven by a news event that has not yet been widely syndicated through major RSS feeds, or it reflects technical factors such as short covering, options-related hedging, or unusual volume activity. Tucows operates in domain registration, email, and telecommunications services. Without headline confirmation, reasonable hypothesis categories include: an earnings surprise or guidance raise that was announced but not yet picked up by tracked feeds, an M&A rumor or concrete transaction proposal, or a technical squeeze among a thinly-traded security. Given the stock's relatively modest market cap and trading volume compared to mega-cap peers, it is more susceptible to these types of disproportionate moves on limited liquidity.

COPR.WT

$1.80+$0.58

+47.5%

TGHL

The GrowHub Limited Class A Ordinary SharesTechnology

$1.11+$0.34

+47.1%

NASDAQ · Mkt cap $17 M

No news headlines were published in the last 48 hours for TGHL, so the 47% gain cannot be attributed to any reported corporate event or market development found in the available news feed.

The absence of recent news headlines makes it impossible to identify a specific catalyst for the 47% intraday jump. TGHL is a thinly traded microcap security, and stocks in this category are particularly susceptible to several non-news-driven mechanisms. The move could reflect technical factors such as short covering or a momentum squeeze, especially if the stock had been oversold or heavily shorted. Alternatively, the gain might stem from delayed dissemination of company announcements, private investor communications, social media activity, or broader sector rotation into small-cap biotech or agricultural holdings. Without access to the company's press releases, SEC filings, or real-time market chatter beyond the Yahoo Finance RSS feed provided, pinpointing the actual cause is not possible. The rank as the number 7 gainer suggests genuine volume and interest, but that alone does not explain the underlying reason.

TGE.WT

The Generation Essentials Group

$0.18+$0.05

+38.5%

NYSE

No news headlines were found in the last 48 hours to explain the 38.46% gain in TGE.WT, making the specific catalyst unclear and likely driven by technical, rumor-based, or delayed news factors.

The absence of recent news from Yahoo Finance RSS makes it impossible to identify a specific catalyst from the headlines provided. TGE.WT is a warrant security, which tends to be more volatile than the underlying stock and can experience outsized moves on modest changes in the underlying asset's price or sentiment. For a small-cap warrant trading at $0.18 to jump 38% in a single day without contemporaneous news coverage suggests either a technical rebound after prior weakness, short-covering activity, retail attention on a message board or social platform, delayed disclosure of earlier news, or speculation ahead of an upcoming event. Without access to the company's calendar or the broader market context for its underlying security, these remain educated guesses rather than identified causes.

SGLY

Singularity Future Technology Ltd.Industrials

$5.31+$1.51

+37.5%

NASDAQ · Mkt cap $2.7 M

No news headlines were found in the last 48 hours, so the 37% gain likely reflects a technical bounce, delayed reaction to older news, or a rumor circulating outside of major financial wire services.

The absence of any recent Yahoo Finance headlines within 48 hours of a 37% single-day jump in a small-cap stock like Singularity Future Technology (SGLY) makes it impossible to identify a specific fundamental catalyst from the information provided. Small-cap and microcap stocks often experience sharp moves on low volume driven by technical factors such as short covering, momentum trading, or chart-based breakouts. It is also possible that material news was released but has not yet been indexed by the RSS feed, or that the move was triggered by discussion on retail trading forums or social media rather than official company announcements. Without a confirmed event, the most honest assessment is that the cause remains unknown from the available evidence.

RYDE

Ryde Group Ltd.Technology

$0.74+$0.20

+36.0%

NYSE · Mkt cap $174 M

No news headlines were available in the last 48 hours for RYDE, so the 36% intraday gain likely reflects a technical rebound, delayed news pickup, or retail interest in a heavily depressed microcap stock trading under $1.

The absence of recent news headlines makes it impossible to identify a specific catalyst for today's move. RYDE is a microcap equity trading at $0.74, a price level typical of highly distressed or penny-stock-range securities. Stocks in this category can experience sharp percentage moves on modest absolute volume, technical bounces from oversold conditions, or belated market reaction to news released outside the monitored window. Without access to pre-market announcements, regulatory filings, or social media activity, the most reasonable hypotheses are a technical mean-reversion move after prolonged decline, short-covering in an illiquid name, or genuine news that simply did not appear in the Yahoo Finance RSS feed within the stated 48-hour window. The rank as the 10th biggest gainer suggests broad market participation, but that alone does not establish a cause.

ELOX

Eloxx Pharmaceuticals IncHealthcare

$17.82+$4.54

+34.2%

NASDAQ · Mkt cap $62 M

No news headlines were found in the last 48 hours, so the 34% gain cannot be attributed to a disclosed public catalyst; the move likely reflects either delayed news publication, technical trading, or an untracked announcement.

Despite a substantial 34% single-day gain ranking ELOX as the eleventh biggest mover on NASDAQ, no recent headlines appear in the Yahoo Finance RSS feed for the last 48 hours. This disconnect suggests either a lag in news aggregation, an after-hours or pre-market event not yet widely reported, or a catalyst from a non-traditional source. For a biopharmaceutical company like Eloxx, typical catalysts include clinical trial results, FDA decisions, partnership announcements, or guidance revisions. The absence of any headline coverage within two days of such a large move is unusual and warrants caution. It is possible a material event occurred but has not yet been picked up by major financial news wires, or the move reflects technical factors such as short covering or options-related activity rather than fundamental news.

WTER

Alkaline Water Co Inc-TheConsumer Defensive

$0.04+$0.01

+32.7%

NASDAQ · Mkt cap $1.1 M

No news headlines were found in the last 48 hours, so the 32.67% gain in WTER stock cannot be attributed to any publicly disclosed event. The move likely reflects technical trading, short covering, or unconfirmed speculation in this micro-cap stock.

No recent news was available to explain WTER's significant single-day rally. This presents a common challenge with penny stocks and micro-cap securities where price moves can occur without corresponding mainstream news coverage. Possible drivers of such moves in illiquid, low-priced stocks include short squeeze dynamics where a small volume of buying pressure forces rapid price appreciation, technical rebounds after oversold conditions, options expiration effects, or social media driven retail trading interest. The stock's rank as the 12th biggest gainer suggests it caught relative market attention, but without news confirmation the catalyst remains speculative. Small-cap biotech or beverage companies like Alkaline Water can see volatility tied to unannounced developments, investor sentiment shifts, or delayed news dissemination through non-traditional channels.

IESC

IES Holdings IncIndustrials

$742.83+$172.15

+30.2%

NASDAQ · Mkt cap $13 B

IES Holdings surged 31% after reporting strong fiscal Q3 2026 earnings and issuing an optimistic outlook for AI data center buildouts, alongside a two-for-one stock split announcement.

The headlines establish two concrete catalysts on July 31st. First, IES Holdings released third quarter fiscal 2026 results and announced a two-for-one stock split, which typically signals management confidence and can mechanically boost price momentum. More substantively, the earnings report came with a "strong outlook for AI data centers," directly tapping into the current market enthusiasm for AI infrastructure plays. The comparison to Microsoft and Amazon rallying the same day underscores that this move reflects genuine sector momentum rather than isolated company news. The 30.17% gain aligns closely with the reported 31% intraday jump, suggesting the market reacted decisively to the combination of solid results and forward guidance tied to the booming AI data center construction cycle. No earnings miss or guidance cut was reported, so this appears a straightforward positive catalyst.

SCYX

SCYNEXIS IncHealthcare

$4.81+$1.03

+27.6%

NASDAQ · Mkt cap $51 M

No news headlines were found in the last 48 hours, so the 27.61% gain likely reflects a delayed reaction to an earlier announcement, technical trading, or a sector-wide catalyst not captured in the RSS feed provided.

SCYNEXIS is a small-cap biotech company, and a nearly 28% single-day jump without contemporaneous headlines is not unusual in this cohort. The gain could stem from several sources: a clinical trial result or regulatory decision announced more than 48 hours ago that is now gaining attention or being repriced by the market, short covering or technical buying after a period of weakness, sector rotation into biotech or antifungal therapeutics, or an unconfirmed rumor circulating among retail or institutional investors. Small-cap biotech stocks are highly sensitive to pipeline progress, FDA interactions, and partnership announcements. Without headlines tied to this specific date, the proximate cause remains obscured. The absence of news in the provided feed does not mean nothing happened; it may reflect a lag in RSS indexing, a company announcement made outside traditional channels, or a market reaction driven by technical factors rather than fundamental news.

FATN

FatPipe, Inc. Common StockTechnology

$6.20+$1.25

+25.5%

NASDAQ · Mkt cap $86 M

FatPipe reported strong Q1 FY2027 earnings with 28% revenue growth to $5.0 million and 65% net income growth, which likely drove the 25.51% single-day jump as investors rewarded the acceleration in profitability and deal-closing momentum.

The company released first-quarter fiscal 2027 results on July 30th showing revenue growth of approximately 27-28% year-over-year to $5.0 million and net income surging roughly 65%, with earnings per share increasing to $0.09 from $0.05 in the prior period. The earnings beat appears tied to Salesforce platform maturation and continued new customer wins. A follow-up analyst report on July 31st highlighted that FatPipe is landing more deals as its Salesforce integration matures, suggesting the underlying business momentum is translating into pipeline success. For a smaller-cap SD-WAN and cybersecurity software company, these profitability and growth metrics represent material operational execution, which explains the magnitude of the equity response.

RYOJ

RYOJBABA CO LTDIndustrials

$5.61+$1.04

+23.6%

NASDAQ · Mkt cap $53 M

No news headlines were found in the last 48 hours for RYOJ, so the 23.58% gain likely reflects technical momentum, a delayed or untracked announcement, or broader market activity in small-cap or emerging market equities rather than company-specific fundamentals.

The absence of any recent news headlines makes it impossible to attribute the significant single-day gain to a specific corporate event such as earnings, guidance revision, partnership, or regulatory approval. RYOJ is a small-cap stock trading on NASDAQ, and such stocks are particularly susceptible to technical rallies, short-covering, retail flow, and sector-wide momentum shifts that may not be immediately captured in mainstream financial news feeds. Another possibility is that a material announcement was made but has not yet been indexed by the Yahoo Finance RSS feed used here, or the move could be driven by activity in the underlying Chinese markets where RYOJ or its parent entities operate. Without corroborating news or structural context, attributing causality is speculative.

ZTEK

Zentek Ltd.Healthcare

$0.68+$0.13

+22.6%

NASDAQ · Mkt cap $75 M

No news headlines were available in the last 48 hours to explain ZTEK's 22.59% gain on July 31, 2026. The spike likely reflects technical trading, delayed news dissemination, or a corporate announcement not yet captured by the RSS feed.

The absence of recent news headlines makes it difficult to pinpoint the exact catalyst for ZTEK's strong 22.59% intraday move. Small-cap stocks listed on NASDAQ, especially those trading below $1.00, are often subject to technical momentum shifts, short covering, or retail interest that can drive rapid price swings independent of fundamental news. It is also possible that a material announcement (earnings, a partnership, regulatory approval, or a capital event) occurred but has not yet propagated through the Yahoo Finance RSS feed used for this snapshot. Without access to company filings, press releases, or social media activity during the trading day, we cannot distinguish between these scenarios. The most prudent assessment is that some event occurred—either a news event with delayed reporting or a pure technical/sentiment-driven move—but the specific cause remains unknown based on the available evidence.

SHPH

Shuttle Pharmaceuticals Holdings IncHealthcare

$3.80+$0.70

+22.6%

NASDAQ · Mkt cap $2.3 M

No news headlines were found in the last 48 hours, so the 22.58% gain likely reflects either a delayed market reaction to an earlier announcement, technical trading, or a catalyst not yet indexed by the RSS feed.

Shuttle Pharmaceuticals is a clinical-stage biopharmaceutical company with a small public float, making it susceptible to sharp single-day moves on modest volume. The absence of headlines in the last 48 hours suggests either that a material event occurred more than two days ago and the market is repricing it now, or that the move reflects technical factors such as short covering, options-driven hedging, or retail trading activity. For small-cap biotech stocks, common catalysts include clinical trial data releases, FDA meeting outcomes, partnership announcements, or insider transactions. Without recent news coverage, pinpointing the specific cause is not possible from the available evidence.

FFAI

Faraday Future Intelligent Electric Inc.Consumer Cyclical

$5.88+$1.13

+21.9%

NASDAQ · Mkt cap $12 M

Faraday Future jumped 21.86% following positive institutional analyst coverage and an FCC policy statement the company believes strengthens its robotics positioning, combined with a reverse stock split announced the prior day.

On July 29, Emerging Growth Research reiterated a Buy rating and raised its 12-month price target to $30, explicitly referencing a reverse stock split. On July 30, the company issued a statement claiming the FCC's new robotics policy enhances its competitive position and announced a global value-chain partner recruitment initiative. The timing and magnitude of the move suggest the analyst upgrade and favorable regulatory narrative provided the primary catalysts. The reverse stock split itself can mechanically move the quoted price and may have attracted fresh investor attention. The company frames itself as an Embodied AI ecosystem player rather than a traditional EV manufacturer, which aligns with emerging growth investor focus. The $30 price target implies substantial upside from the $5.88 level, likely driving momentum buying. No concrete product milestones, earnings, or customer wins were disclosed in the available headlines.

RCON

Recon Technology LtdEnergy

$0.44+$0.08

+21.8%

NASDAQ · Mkt cap $1.7 M

Recon Technology announced a $100 million at-the-market equity offering program on July 31, which likely drove the 21.81% intraday gain as investors responded positively to the capital raise announcement and potential strategic optionality.

The single news headline from Yahoo Finance confirms that Recon Technology announced an at-the-market (ATM) equity offering program for $100 million on the same day as the stock's 21.81% jump to $0.44. An ATM offering allows a company to issue shares gradually at market prices, providing liquidity without the dilution risk of a large single-tranche offering. For a micro-cap stock trading at $0.44, a $100 million capital raise represents material financing flexibility. The positive market reaction suggests investors interpreted this announcement as a sign of financial stability, access to capital, or upcoming growth initiatives that the company plans to fund. Without additional context about the company's cash position, burn rate, or strategic plans, the exact nature of what the capital will fund remains unclear. However, the timing of the announcement and the stock's immediate positive response indicate market participants viewed it favorably, possibly seeing it as enabling future operations or acquisitions in Recon's oilfield services and environmental protection segments.

FET

Forum Energy Technologies IncEnergy

$62.45+$11.08

+21.6%

NYSE · Mkt cap $939 M

Forum Energy Technologies surpassed Q2 earnings estimates by over 100% and raised full-year 2026 guidance on July 30, driving a 21.57% gain the following day as investors repriced the stock on stronger-than-expected profitability and operational execution.

The headline record shows that FET reported earnings and revenue surprises of +103.51% and +6.53% respectively for Q2 2026, ending June 30. The company cited market-share gains, higher-margin product mix, and cost actions as drivers. Most significantly, management raised full-year 2026 guidance following this outperformance. An earnings beat of that magnitude—especially a tripling of profit expectations—typically triggers substantial upward repricing, particularly when coupled with a forward guidance raise. The 21.57% single-day gain is consistent with the magnitude of the surprise. The earnings call highlights reinforced execution across operating segments, which addresses investor concerns about operational credibility.

ITGR

Integer Holdings CorpHealthcare

$121.23+$20.31

+20.1%

NYSE · Mkt cap $4.3 B

Integer Holdings surged 21% on a Wall Street Journal report that KKR is near a deal to take the medical-device outsourcing company private, driving a significant valuation premium on takeover optimism.

The headline directly establishes a pending private-equity acquisition by KKR as the driver of the stock move. Integer Holdings is a medical-device outsourcing company, a sector where strategic buyouts and consolidation are routine. The WSJ report, which cites informed sources close to a deal, is treated by the market as highly credible signal of an impending transaction. Investors are bidding the stock up in anticipation of deal completion at a premium to the pre-announcement price. The 21% single-day move is typical for announced or near-certain M&A events, reflecting the gap between current price and expected takeout price. No conflicting news is present in the headlines provided.

ZTG

Zenta Group Company LimitedIndustrials

$4.45+$0.66

+20.0%

NASDAQ · Mkt cap $30 M

No news headlines were found in the last 48 hours for ZTG, so the 20% gain on July 31, 2026 cannot be attributed to a specific announced catalyst. The move likely reflects technical trading, delayed news dissemination, or undisclosed market activity.

The absence of any Yahoo Finance headlines in the 48-hour window preceding this 20% rally is notable. For a stock ranking 23rd among daily gainers, one would typically expect at least one headline if a material corporate event (earnings, guidance, partnership, or regulatory decision) had occurred. The move could reflect several non-news-driven mechanisms: short covering in a thinly traded or volatile name, technical breakout above resistance levels, retail or algorithmic trading activity, delayed or localized news not yet reflected in major feeds, or simply market rotation into a small-cap name. Without headline confirmation or knowledge of ZTG's specific business fundamentals, float, short interest, or technical setup, attribution remains speculative.

NUCLW

Eagle Nuclear Energy Corp. Warrants

$0.90+$0.15

+20.0%

CIGL

Concorde International Group Ltd Class A Ordinary SharesIndustrials

$0.60+$0.09

+19.8%

NASDAQ · Mkt cap $100 M

No news headlines were found in the last 48 hours for CIGL, so the 19.81% gain likely reflects technical trading activity, delayed news dissemination, or market speculation on a low-priced stock rather than a specific corporate announcement.

The absence of recent news headlines makes it impossible to identify a concrete catalyst for CIGL's nearly 20% single-day gain. Penny stocks and low-priced shares often exhibit outsized percentage moves on modest absolute trading activity, which can be driven by several non-news factors. Possible explanations include technical breakouts, retail trading momentum, short covering, or delayed reporting of company announcements not yet indexed by major news feeds. Additionally, stocks trading near support levels can experience sharp bounces on minimal volume. Without access to intraday trading data, social media chatter, or company press releases issued directly, it is not possible to narrow the cause further. The timing mismatch between the price action and the news vacuum suggests either the move preceded formal news dissemination or was driven entirely by market technicals and sentiment unrelated to new information.

NRSN

NeuroSense Therapeutics Ltd.Healthcare

$0.46+$0.09

+19.3%

NASDAQ · Mkt cap $14 M

No news headlines were found in the last 48 hours, so the 19.31% gain likely reflects either a delayed market reaction to an earlier announcement, short-covering, or speculative trading in this micro-cap biotech stock.

NeuroSense Therapeutics is a small-cap neurological disease-focused biotech company trading at $0.46 per share. The stock ranks 26th among daily gainers despite the absence of any identified news in the past two days. For micro-cap biotech stocks at this price level, significant single-day moves often occur due to technical factors rather than fundamental news: short squeezes are common given high short interest typical in this sector, retail accumulation can drive rapid rallies, or the market may be reacting to news released more than 48 hours prior that hasn't yet been widely distributed through major feeds. Alternatively, an announcement may have occurred through a press release or filing that hasn't yet propagated to Yahoo Finance's RSS feed. Without access to the company's recent filings, clinical trial updates, or partnership announcements, attributing the move to a specific catalyst is not possible.

GCDT

Green Circle Decarbonize Technology LimitedIndustrials

$0.39+$0.06

+19.2%

NYSE · Mkt cap $5.2 M

No news headlines were found in the last 48 hours, so the 19.21% gain cannot be attributed to a specific announced event. The jump likely reflects technical trading, delayed news digestion, or market speculation typical of micro-cap green-tech stocks.

Yahoo Finance returned zero headlines for Green Circle Decarbonize Technology Limited in the 48-hour window ending July 31, 2026. Without a specific catalyst in the news record, the substantial single-day gain of 19.21% remains unexplained by documented public information. For a small-cap decarbonization technology company trading at $0.39, typical drivers of such moves include renewed investor interest in ESG themes, short-covering in a thinly traded stock, technical breakouts above prior resistance, or delayed market reaction to company announcements not yet indexed by the RSS feed. It is also possible the stock was mentioned in social media, analyst notes, or insider activity not yet reflected in headline sources. Without corroborating news, attribution is speculative.

CNSP

CNS Pharmaceuticals IncHealthcare

$5.82+$0.94

+19.2%

NASDAQ · Mkt cap $8.5 M

No news headlines were published in the last 48 hours regarding CNSP, so the 19.2% gain on July 31 cannot be attributed to a confirmed catalyst; the jump may reflect technical trading, delayed market reaction to older news, or unindexed developments.

The absence of any recent news in the Yahoo Finance RSS feed over the prior 48 hours means we cannot point to a specific earnings report, FDA decision, clinical trial result, partnership announcement, or guidance change as the direct cause of CNSP's strong single-day performance. CNS Pharmaceuticals is a small-cap biopharmaceutical company, and stocks in this sector often respond sharply to clinical data releases, regulatory milestones, or insider activity that may not immediately appear in major news aggregators or may circulate through specialized channels ahead of broad distribution. Alternatively, the move could reflect technical momentum, short covering, or reaction to news published more than 48 hours prior that is only now driving trading volume. Without headline confirmation, attributing the jump to a specific event would be speculation.

SOC

Sable Offshore CorpEnergy

$5.29+$0.83

+18.6%

PWP

Perella Weinberg PartnersFinancial Services

$17.65+$2.73

+18.3%

NASDAQ · Mkt cap $1.6 B

Perella Weinberg Partners jumped 18.26% after reporting Q2 2026 earnings that beat Wall Street's profit expectations, with adjusted EPS of $0.20 and revenue of $157 million, despite modest year-over-year growth.

The headlines establish that PWP reported second-quarter results on July 31, 2026, delivering earnings that "crushed Wall Street's profit expectations" according to one source. The company posted adjusted EPS of $0.20 and revenue of $157 million, up 1% year-over-year. Multiple sources note the earnings beat and cite accelerating transaction announcements and revenue backlog as forward indicators. The company also announced the promotion of eight Managing Directors to Partners on the same day. While revenue growth appears modest in absolute terms, the consensus from the headlines is that the profitability metrics exceeded analyst forecasts, which typically drives single-day rallies in financial advisory stocks. The combination of an earnings beat plus positive forward signals appears sufficient to explain the 18% gain.

FVN

Future Vision II Acquisition Corporation Ordinary sharesFinancial Services

$11.00+$1.67

+17.9%

NASDAQ · Mkt cap $88 M

No news headlines were available in the last 48 hours, so the 17.90% gain cannot be attributed to a specific announced event; the move likely reflects SPAC warrant redemption activity, redemption deadline pressure, or market speculation on a pending merger announcement.

Future Vision II Acquisition Corporation is a SPAC (special purpose acquisition company), a security type that frequently experiences sharp price moves disconnected from traditional news cycles. The +17.90% jump in the absence of any reported headlines suggests the move may stem from internal SPAC mechanics rather than external catalysts. Common SPAC-driven catalysts include approaching warrant redemption deadlines, redemption ratio changes, or anticipation of a merger announcement not yet picked up by news feeds. SPACs can also experience technical or momentum-driven rallies as redemption dates approach and holders reassess positions. Without access to the SPAC's specific timeline, warrant terms, or internal corporate calendar, we cannot pinpoint which of these mechanisms drove today's gain.

CALC

CALCIMEDICA INCHealthcare

$1.00+$0.15

+17.7%

NASDAQ · Mkt cap $19 M

No news headlines were found in the last 48 hours, so the 17.75% gain on CALC likely stems from technical trading activity, delayed news flow, or market rumors not captured in Yahoo Finance RSS feeds.

Calcimedica Inc is a small-cap biotech stock trading at $1.00, and the absence of any recent news headlines makes it difficult to pinpoint a specific catalyst for today's 17.75% jump. Small-cap and micro-cap biotech stocks are particularly sensitive to technical factors such as short covering, options expiry-related buying, or index rebalancing. It is also possible that relevant news was released through channels not indexed by Yahoo Finance RSS, or that the move reflects accumulated positive sentiment from earlier announcements. Without access to trading volume, short interest data, or company press releases directly, the most likely explanations fall into technical or sentiment-driven categories rather than fundamental corporate events.

BLBX

Blackboxstocks Inc.Basic Materials

$8.78+$1.29

+17.2%

NASDAQ · Mkt cap $63 M

No headlines were published in the last 48 hours, so the 17.22% gain cannot be directly tied to recent company news. The move may reflect technical trading, retail interest, or delayed market reaction to an unindexed event.

Despite a significant single-day jump of 17.22% that placed BLBX among the top 33 gainers on NASDAQ, no financial news headlines appeared in the Yahoo Finance RSS feed during the preceding 48 hours. This disconnect between price action and visible news creates ambiguity about causation. For a stock like BLBX, which operates in the trading-technology space, moves of this magnitude in the absence of published headlines typically stem from one of several categories: technical factors such as short covering or options expiration effects, retail trading sentiment shifts often coordinated on social platforms without traditional press coverage, or delayed market digestion of earlier company announcements that did not generate fresh headlines. Without accompanying fundamental news, attributing the move to company-specific positive developments remains speculative. The silence from major news sources suggests either that the catalyst is non-fundamental in nature or that relevant information has not yet reached mainstream financial outlets.

DSY

Big Tree Cloud Holdings Limited Ordinary SharesConsumer Defensive

$3.77+$0.55

+16.9%

NASDAQ · Mkt cap $18 M

No news headlines were found in the last 48 hours, so the 16.9% gain likely reflects delayed market reaction to a prior announcement, technical trading, or an untracked catalyst.

No recent news headlines are available to explain the move directly. Big Tree Cloud Holdings is a smaller-cap cloud software company listed on NASDAQ. A one-day jump of this magnitude in a stock without same-day headline coverage typically indicates one of three scenarios: first, a delayed market reaction to news released before the 48-hour window; second, a technical catalyst such as short covering, options expiration dynamics, or a stock upgrade from an analyst not captured by Yahoo Finance RSS; or third, an untracked corporate development, partnership announcement, or insider transaction that moved retail or institutional buyers. Without access to prior news or real-time market chatter, we cannot distinguish among these. The 16.9% move is substantial enough to suggest real information flow rather than pure noise, but the source remains opaque from the available evidence.

IAUX.WT

i-80 Gold Corp. WT

$0.70+$0.10

+16.6%

FORR

Forrester Research IncIndustrials

$11.45+$1.63

+16.5%

NASDAQ · Mkt cap $217 M

Forrester Research beat Q2 2026 earnings expectations by 48% and reported a 69% year-over-year surge in AI adoption, offsetting revenue declines in consulting and events, which drove the 16.55% stock rally.

Forrester reported Q2 2026 results that exceeded internal expectations with a significant earnings surprise of 48.15% and a modest revenue beat of 3.42%. The most notable positive signal was a 69% year-over-year increase in AI adoption among clients, demonstrating strong demand for the company's AI-focused research and advisory services. While the company acknowledged continued revenue headwinds in its consulting and events segments, management highlighted progress toward contract value growth targets by end of 2026. Contract value stood at $283.2 million, down 3% year-over-year, but the substantial earnings beat combined with the AI momentum narrative appears to have reassured investors that the company is successfully pivoting its business model despite near-term revenue pressures. The 16.55% gain reflects relief at the beat and optimism about the AI tailwind offsetting structural declines elsewhere.

ATHHF

Aether Catalyst Solutions Inc.Consumer Cyclical

$0.01+$0.00

+16.4%

AMBA

Ambarella IncTechnology

$85.98+$11.84

+16.0%

NASDAQ · Mkt cap $2.9 B

NXP Semiconductors is in acquisition talks with Ambarella, a major AI-powered chip designer for autonomous vehicles and security systems, triggering a 16% intraday spike on Friday.

Multiple Financial Times reports published Friday afternoon confirmed that NXP, a major Dutch chipmaker, is actively discussing an acquisition of Ambarella. The news broke around 17:06 UTC and drove shares up approximately 18% by market close. Ambarella designs AI-enabled camera chips for self-driving vehicles and security applications, making it a strategically valuable asset in the rapidly growing autonomous driving and edge AI markets. The acquisition would likely provide NXP with specialized imaging and AI processing capabilities while offering Ambarella shareholders a path to liquidity at a significant premium to recent trading levels. At a market cap of $3.25 billion, the deal size is material but not transformative for NXP. The headline explicitly states these are "talks" rather than a signed agreement, so deal risk and financing contingencies remain, but the headline evidence directly connects the stock move to M&A speculation.

CCG

Cheche Group Inc. - Class A Ordinary SharesCommunication Services

$15.19+$2.09

+16.0%

NASDAQ · Mkt cap $34 M

No news headlines were found in the last 48 hours for CCG, so the 15.95% gain likely stems from technical factors, delayed news digestion, or market rumors rather than a confirmed corporate announcement.

The absence of recent headlines in the Yahoo Finance RSS feed makes it difficult to pinpoint a specific catalyst for CCG's strong single-day gain. Cheche Group Inc. is a relatively small-cap NASDAQ stock, and such securities can experience significant intraday moves on thin volume, short covering, or delayed market reaction to older news not yet indexed by RSS feeds. Without access to the company's fundamentals, recent earnings, guidance changes, or sector-specific catalysts, the most likely explanations fall into behavioral or technical categories: short squeeze activity, retail flow, or a delayed pickup on news released before the 48-hour window. Institutional research or real-time company filings would be needed to distinguish between these possibilities.

FNGR

FingerMotion, Inc.Communication Services

$0.27+$0.04

+15.9%

NASDAQ · Mkt cap $14 M

No news headlines were found in the last 48 hours, so the 15.91% gain on FNGR likely reflects a technical rebound, delayed market reaction to older news, or speculative trading activity in a micro-cap stock.

The absence of any recent news headlines makes it impossible to tie this movement to a specific corporate event. FNGR is a micro-cap stock trading at $0.27, a category that typically exhibits high volatility and can move sharply on thin volume, short covering, retail interest, or delayed reactions to older announcements. Without access to intraday trading data or confirmation of any news released outside the Yahoo Finance RSS feed, the most likely explanations are either a technical bounce after recent weakness, accumulation by retail traders or institutions, or coverage of a development that has not yet appeared in mainstream financial news feeds. Sector rotation into fintech or payment services could also have contributed if such a move occurred broadly.

GLND

Greenland Energy CompanyEnergy

$2.27+$0.31

+15.9%

NASDAQ · Mkt cap $62 M

Greenland Energy announced its Jameson Project is gaining attention amid rising geopolitical tensions and energy security concerns, likely driving investor interest in the company's Greenland-based energy assets as a strategic alternative energy source.

The single headline from July 30 indicates that GLND issued a press release positioning its Jameson Land Basin project as relevant to broader energy security discussions tied to geopolitical tensions. The incomplete headline text does not provide specifics on new contracts, permits, or strategic partnerships, but the framing suggests the company is benefiting from renewed focus on energy independence and non-traditional supply sources. A 15.9% single-day move on this type of thematic positioning is noteworthy and suggests either meaningful investor reallocation into energy security plays or possible short covering. Without fuller details on the announcement's content—such as specific customer commitments or project milestones—the exact catalyst remains partially obscured, though the timing around heightened geopolitical risk appears material to the stock's appeal.

MODD

Modular Medical, Inc.Healthcare

$2.39+$0.33

+15.7%

NASDAQ · Mkt cap $13 M

No news headlines were found in the last 48 hours, so the 15.74% gain likely reflects either a delayed market reaction to earlier developments, short covering, technical buying, or an unindexed announcement not yet surfaced in major news feeds.

The absence of any news headlines in the most recent 48 hours makes it difficult to pinpoint a specific catalyst for MODD's strong +15.74% one-day gain. For a small-cap medical device company trading at $2.39, several common drivers could explain intraday surges without immediate news coverage: a technical breakout or short squeeze (especially common in lower-priced equities with concentrated short interest), execution of a previously announced deal or regulatory milestone, an earnings release or guidance announcement that has not yet propagated through major news aggregators, or simply thin-liquidity trading on modest volume. Additionally, small-cap biomedical stocks sometimes gap on insider transactions, clinical trial results posted directly to company websites before formal press releases, or coverage by retail investment communities that precedes institutional news dissemination.

SKYQ

Sky Quarry Inc.Energy

$4.63+$0.65

+15.7%

NASDAQ · Mkt cap $12 M

No news headlines were found in the last 48 hours, so the 15.66% gain cannot be traced to a specific announced catalyst; the move may reflect technical trading, delayed news circulation, or unconfirmed market rumors.

Sky Quarry Inc. posted a substantial single-day gain of 15.66%, ranking it among the top 43 gainers on NASDAQ, yet no financial news appeared in the Yahoo Finance RSS feed over the preceding 48 hours. This disconnect suggests either that the catalyst was not widely picked up by major news outlets, occurred in after-hours trading on the prior day, or is rooted in technical or sentiment factors rather than a disclosed event. For a small-cap stock like SKYQ, potential drivers could include short covering, options-related gamma activity, sector-wide momentum, or an unconfirmed business development announcement that has not yet reached mainstream financial press. Without corroborating headlines or known structural characteristics of the security, pinpointing the exact cause remains speculative.

ALVO

AlvotechHealthcare

$4.12+$0.56

+15.6%

NASDAQ · Mkt cap $1.4 B

No news headlines were reported in the last 48 hours, so the 15.59% gain on ALVO lacks an obvious catalyst. The jump may reflect short covering, technical bounce, sector momentum, or delayed disclosure of a company development.

Yahoo Finance returned no headlines for Alvotech in the 48-hour window preceding this snapshot. Without news coverage, the cause of a 15% single-day jump remains speculative. Alvotech is a biosimilar developer, a sector sensitive to clinical trial results, regulatory approvals, partnership announcements, and manufacturing updates. A typical catalyst for a stock in this space might include positive Phase III data, FDA or EMA action on a pending application, a licensing deal, or short-squeeze activity if the stock has high short interest. Without confirmed information, all explanations are hypothetical. It is also possible that a material announcement was issued but simply not yet picked up by the RSS feed source provided.

BHC

Bausch Health Cos IncHealthcare

$6.91+$0.92

+15.5%

NYSE · Mkt cap $2.5 B

Bausch Health surged 15.46% following strong Q2 2026 earnings results that beat revenue and earnings estimates, driven by growth in Salix and Solta Medical divisions, coupled with raised full-year 2026 guidance.

The headlines establish that Bausch Health reported Q2 earnings on July 29-30 that delivered an earnings surprise of +31.25% and a revenue surprise of +7.62%. Management highlighted 13 consecutive quarters of revenue and adjusted EBITDA growth, with particular strength in the Salix and Solta Medical segments. The company raised its 2026 revenue and EBITDA guidance following these results. One headline references a 28% single-day jump attributed to the earnings announcement, though the snapshot shows a 15.46% gain, which may reflect the closing price after some of the initial spike. The earnings beat combined with forward guidance raise is a textbook catalyst for healthcare stock appreciation, especially for a company recovering from prior struggles. The strength appears company-specific and directly tied to operational execution rather than sector-wide factors, as the broader healthcare index declined that afternoon.

AMCX

AMC Networks IncCommunication Services

$11.19+$1.47

+15.1%

NASDAQ · Mkt cap $493 M

AMC Networks stock surged 15% on July 31 after announcing a $500 million Walking Dead licensing deal with Netflix on July 30, which prompted analyst upgrades and a raised full-year outlook despite missing Q2 revenue estimates.

The catalyst is clear from the headline sequence. On July 30, AMCX reported Q2 earnings that missed revenue estimates by 2.7% and posted a non-GAAP loss, which normally would pressure the stock. However, the company simultaneously disclosed a five-year global co-exclusive streaming licensing agreement for The Walking Dead intellectual property with Netflix worth $500 million. Management raised full-year guidance on the back of this deal. By July 31, Wall Street analysts responded positively, with Wells Fargo noting the agreement should provide material cash flow and improve balance-sheet stability. For a media company struggling with declining revenue, a half-billion-dollar licensing deal for a flagship IP franchise represents a meaningful near-term cash injection and signals that valuable franchises retain market demand, even as the company's traditional broadcast business contracts. The 15% one-day gain reflects relief from the revenue miss being overshadowed by the strategic win.

AEMD

Aethlon Medical IncHealthcare

$0.65+$0.08

+14.7%

AEON

AEON Biopharma, Inc.Healthcare

$0.30+$0.04

+14.7%

NYSE · Mkt cap $9.9 M

No news directly mentioning AEON Biopharma was provided; the 14.65% gain likely reflects a small-cap biotech stock responding to positive sector momentum or an undisclosed catalyst not captured in the headlines.

The single headline provided discusses Humana and Las Vegas Sands upgrades and downgrades but makes no mention of AEON Biopharma or any related development. This disconnect suggests the stock's gain may stem from a catalyst not represented in the available news feed, or from broad sector dynamics affecting small-cap biotech names. Biotech stocks, particularly those trading near $0.30, are often sensitive to early-stage trial data releases, partnership announcements, or regulatory milestones that may not immediately surface in major financial news aggregators. Alternatively, the move could reflect technical buying, short covering, or liquidity events common in lower-priced equities. Without specific news tied to AEON itself, the immediate cause remains unclear.

ROCL

Roth Ch Acquisition V Co.Financial Services

$4.66+$0.59

+14.5%

NASDAQ · Mkt cap $27 M

No headlines were found in the last 48 hours explaining ROCL's 14.50% gain, so the catalyst remains unclear without additional information.

Roth Ch Acquisition V Co. is a special purpose acquisition company (SPAC), a structure that often experiences sharp price moves on deal announcements, merger closing dates, warrant exercises, or redemption activity even without major news appearing in broad financial headlines. The stock jumped to $4.66, which sits just above typical SPAC par value, suggesting the move may reflect either positive sentiment around a pending transaction, a scheduled corporate action, or technical buying. However, without access to press releases, SEC filings, or deal announcements made within the 48-hour window, the specific trigger cannot be identified from the evidence provided. SPAC-related catalysts often appear first in company disclosures or specialized sources before general news aggregation catches them.

CDNA

CareDx IncHealthcare

$43.69+$5.53

+14.5%

NASDAQ · Mkt cap $2.6 B

CareDx reported a 52% revenue beat with earnings surprise of +68% in Q2 2026, completed a strategic lab products sale, and expanded testing services, positioning itself as a precision medicine leader and triggering the 14.5% stock jump.

The news headlines establish that CareDx reported earnings and revenue on July 30, significantly beating analyst expectations. The company delivered a 68% earnings surprise and 15% revenue surprise, with Q2 revenue growing 52% year-over-year. Beyond the headline beat numbers, CareDx completed the sale of its lab products business and began integrating a recent acquisition, both of which suggest management is reshaping the company toward higher-margin precision diagnostics in transplant and specialty oncology. The July 31 headlines reference acceleration toward precision medicine and the stock reaching a buy point on a bullish chart pattern, indicating strong technical follow-through. The magnitude of the move (14.5% gain, ranking 50 of the day) is consistent with a robust earnings surprise combined with positive forward guidance or operational achievements signaled during the earnings call.

Biggest Losers

Fri, Jul 31, 2026 50

JDZG

JIADE LimitedConsumer Defensive

$5.85−$44.89

-89.8%

NASDAQ · Mkt cap $23 M

JIADE announced resumption of trading on Nasdaq after a halt, triggering a massive 89.78% sell-off, likely driven by a flood of pent-up selling pressure or negative news that emerged during the trading suspension.

The headline confirms that Nasdaq advised JIADE that trading in its Class A ordinary shares would resume on July 30, 2026. The timing of the announcement and the extreme single-day decline suggests the stock was halted prior to this date, possibly due to pending news or a corporate event. When trading resumes after a halt, particularly one lasting several days or longer, shareholders often rush to exit positions if they received adverse information during the blackout period—such as disappointing earnings, a failed funding round, regulatory issues, or delisting risk warnings. The 89.78% drop is consistent with a capitulation sell-off following either a negative catalyst revealed during the halt or loss of investor confidence in the company's viability. Without the full trading halt notice or underlying reason for suspension, the precise trigger remains unclear, but the magnitude suggests a fundamental problem rather than technical selling.

KPTI

Karyopharm Therapeutics IncHealthcare

$1.91−$5.09

-72.7%

NASDAQ · Mkt cap $45 M

Karyopharm's Phase 3 XPORT-EC-042 trial of selinexor for endometrial cancer failed to meet its primary endpoint, announced after-hours on July 30, causing a 72.71% single-day plunge in stock price.

The evidence directly links the stock collapse to the clinical trial failure. On July 30 after-hours, Karyopharm announced topline results from the Phase 3 XPORT-EC-042 study showing that selinexor as a main treatment for endometrial cancer did not meet its primary goal in a randomized, double-blind, placebo-controlled trial of 257 adults. This represents a significant setback for a late-stage asset in what appears to be a key indication for the company's pipeline. The same day the company also announced plans to pursue an accelerated approval pathway for a different combination therapy (selinexor plus ruxolitinib in myelofibrosis), but that positive news was overshadowed by the endometrial cancer trial failure, which likely was viewed as a more immediately material asset.

DFNS

Defense Industries International IncIndustrials

$28.00−$56.96

-67.0%

NYSE · Mkt cap $27 M

DFNS fell 67% despite a positive earnings-related announcement from T3 Defense reporting record year-to-date revenue and order intake, suggesting the market reaction was driven by something other than the headline news or a major unannounced negative event.

The provided headline shows T3 Defense (ticker DFNS) reporting strong operational results with record revenue, new order intake, and backlog levels. This is typically positive news that would support or lift a stock price. However, the stock crashed 67% on the same day the announcement was published, which is a severe disconnect. The headline excerpt is incomplete and cuts off mid-sentence, so critical details may be missing—such as disappointing guidance, margin compression, dividend elimination, a major contract loss, or an unrelated corporate action. Alternatively, the positive news may have been overshadowed by a material development not captured in the provided headlines, such as management changes, regulatory issues, or a broader market event affecting defense contractors.

BIOA

BioAge Labs, Inc.Healthcare

$9.03−$15.84

-63.7%

NASDAQ · Mkt cap $493 M

No headlines were reported in the last 48 hours, so the 63.68% drop on BIOA cannot be attributed to disclosed news; it likely reflects either a delayed market reaction to an unreported event, insider/institutional selling, or an unfavorable earnings or clinical announcement released outside the t…

BioAge Labs is a clinical-stage biotech company focused on aging and longevity research, a sector sensitive to regulatory outcomes, clinical trial results, and funding developments. The absence of any Yahoo Finance headlines in the 48 hours surrounding this major decline is noteworthy and suggests either that the catalyst occurred before the snapshot window, that it was announced through a channel not captured by the RSS feed, or that the market is reacting to non-public information. For early-stage biotech stocks like BIOA, typical high-impact catalysts include adverse clinical trial data, FDA feedback letters, failed regulatory meetings, capital raises at steep discounts, insider selling, or short-seller reports. The magnitude of the decline warrants investigation into company filings, press releases issued directly by the company, and recent short-interest activity, none of which are available in the provided data.

MBRX

Moleculin Biotech IncHealthcare

$0.40−$0.61

-60.9%

NASDAQ · Mkt cap $4.3 M

Moleculin announced a $9.3 million dilutive public offering of 12.4 million shares on the same day it reported positive interim trial data, triggering a 60.85% sell-off likely driven by shareholder dilution and timing concerns despite the clinical win.

Moleculin released two significant pieces of news on July 31st. The positive interim data from the MIRACLE trial showing 37% blinded composite remission in venetoclax-failed AML patients is objectively encouraging, beating the historical salvage remission rate of approximately 13%. However, the same-day announcement of a best-efforts public offering of 12.4 million shares at $0.75 per share represents substantial dilution to existing shareholders. In biotech, the market often penalizes equity raises even when accompanied by positive clinical data, as dilution immediately reduces ownership percentage and future earnings per share. The magnitude of the decline suggests investors viewed the offering as poor timing or an indication that the company needed capital urgently, potentially overriding enthusiasm from the trial results. Best-efforts offerings carry execution risk as well, since the company is not guaranteed to raise the full amount.

CYCU

Cycurion, Inc. Common StockTechnology

$0.89−$1.30

-59.7%

NASDAQ · Mkt cap $7.9 M

Cycurion plummeted 59.68% after a massive 496% surge on Thursday driven by a $54.6M government contract announcement, likely due to profit-taking and a concurrent dilutive warrant offering announced on July 31st.

The stock experienced an extraordinary two-day swing. On Thursday July 30, Cycurion announced a 10-year, $54.6 million government contract with a top-5 consulting firm, triggering a 496% rally. The stock gained another 37% in premarket trading on Friday. However, on July 31, the company announced a warrant inducement transaction for $4.5 million in gross proceeds, which represents equity dilution to existing shareholders. The collapse on July 31 reflects a combination of factors: aggressive profit-taking after the extreme rally, negative market reaction to the dilutive financing announcement, and likely a recognition that even a major contract win does not guarantee near-term profitability for a micro-cap stock. The timing of announcing the warrant offering on the same day as the pullback suggests investors may have perceived poor capital allocation timing following the contract news.

INHD

Inno Holdings Inc.Basic Materials

$18.18−$21.81

-56.9%

NASDAQ · Mkt cap $36 M

Inno Holdings stock plummeted 56.93% following the announcement of trading resumption on Nasdaq after an apparent halt, suggesting severe negative developments during the trading suspension period.

The two news headlines from July 30 announce the resumption of trading on Nasdaq, but they do not disclose why trading was halted in the first place or what triggered the resumption. This is a critical gap. When a stock resumes trading after suspension and immediately drops 57%, the cause is typically either a material adverse development disclosed during the halt, a delisting concern that was resolved but revealed poor fundamentals, regulatory action, or reverse split announcement. The timing suggests the market is pricing in bad news that became public or re-public at or around the resumption. Without access to the actual trading halt reason, the specific SEC filings, or any negative business announcement, the exact catalyst remains opaque. This pattern is consistent with companies experiencing significant governance issues, accounting concerns, failed financing, or sudden operational crises.

SZZL

Sizzle Acquisition Corp.Financial Services

$5.49−$4.89

-47.1%

NASDAQ · Mkt cap $327 M

No news headlines were published in the last 48 hours, so the 47% drop cannot be attributed to a specific disclosed event. The move likely reflects a development not yet captured by financial news feeds or a market-wide correction affecting blank-check companies.

The absence of any recent news is striking given the magnitude of the decline. SZZL is a SPAC (special purpose acquisition company), a category of shell companies that historically experience large single-day moves tied to merger announcements, deal terminations, warrant redemptions, or shareholder voting outcomes. The stock's 47% plunge could stem from several sources typical for SPACs: failure of a proposed merger to be approved, announcement of deal termination, unexpected redemptions by shareholders, or unfavorable terms of a pending combination becoming public. Alternatively, the move could reflect a technical event such as a reverse split announcement, rights offering, or broad-market deleveraging affecting SPAC valuations. Without headline evidence, the true catalyst remains opaque.

MYGN

Myriad Genetics IncHealthcare

$2.87−$2.51

-46.6%

NASDAQ · Mkt cap $292 M

Myriad Genetics reported Q2 2026 earnings on July 30 that missed revenue estimates and triggered a 28.6% initial drop, with the full-year guidance cut and 11% year-over-year revenue decline as the primary drivers of the near-47% one-day loss.

The headlines establish that Myriad reported Q2 revenue of $190.7 million, down 11% year-over-year and below analyst expectations, with a significant miss on earnings (down 733.33% to a loss). The company cited reimbursement headwinds from payers as a key factor, lowering full-year 2026 revenue guidance to $770–$790 million. The decline in average revenue per test (down 9% year-over-year) and volume (down 1%) together paint a picture of margin compression and demand weakness in the genetic testing market. The stock had already dropped 28.6% by July 30 evening; the additional 18 percentage points of decline by the July 31 snapshot suggests either continued selling pressure at open or a secondary negative catalyst or analyst downgrade on July 31 morning that the headlines do not yet capture.

GCTK

GlucoTrack, Inc.Healthcare

$0.45−$0.32

-41.3%

NASDAQ · Mkt cap $3.7 M

GlucoTrack announced expansion of its ai² Futures Lab and progress on the LT-100 development program, but the market sold off 41% anyway, suggesting the news itself was not the primary driver of the decline.

The two news items released in the last 48 hours are both positive operational announcements from GlucoTrack and its subsidiary Lōkahi Therapeutics: expansion of the ai² Futures Lab pipeline-building platform and advancement of LT-100 toward single-injection administration. Neither headline indicates a setback, failed trial, withdrawn application, or negative guidance revision. The timing of the first announcement (same day as the crash) and second (two days prior) does not align cleanly with a 41% single-day plunge triggered by the news itself. This suggests either a delayed negative catalyst not captured in the headlines provided, a broader market or sector rotation, technical selling pressure in a low-float microcap stock, or an undisclosed development that precipitated the move. Biotech microcaps are highly volatile and susceptible to sentiment shifts and funding concerns.

NUWE

Nuwellis, Inc.Healthcare

$1.75−$1.14

-40.9%

NASDAQ · Mkt cap $3.7 M

Nuwellis announced a $3.4 million registered direct offering at-the-market pricing on July 31, which typically dilutes existing shareholders and triggered the 40.85% intraday sell-off.

The timing and magnitude of the decline align directly with the registered direct offering announcement. When a micro-cap biomedical device company like Nuwellis prices a capital raise at-the-market, it signals management believes the current stock price is a reasonable exit point for raising cash, which can be interpreted as undervaluation by the market and triggers immediate shareholder dilution concerns. The offering was announced the same day as the stock's largest decline, making it the primary catalyst. The positive news on July 30 regarding the Aquadex pediatric study acceptance did not arrest the selling pressure once the offering was disclosed. The company also received $3.1 million from warrant exercises, adding further dilution to the share count.

GENVR

Gen Digital Inc. Contingent Value Rights

$1.18−$0.70

-37.2%

NASDAQ

No news headlines are available in the last 48 hours to explain the 37% decline in GENVR, a contingent value rights security whose price movements are typically tied to merger completion risk or changes in deal terms.

No headlines were found in the last 48 hours, making it impossible to identify a specific catalyst for this sharp decline. However, GENVR is a contingent value right (CVR), meaning its value is tied to the occurrence or non-occurrence of a specific future event, typically completion of an acquisition at certain terms. These securities are highly sensitive to changes in deal probability, regulatory risk, or public statements from either party that signal deal delay, renegotiation, or termination risk. The 37% drop suggests a material deterioration in market expectations around the underlying deal outcome. Without access to recent news, the likeliest categories of catalyst are adverse M&A developments, regulatory setback, or a material announcement from the acquiring or acquired company within the past 48 hours that was not captured in the provided headline feed.

VMAR

Vision Marine Technologies Inc.Consumer Cyclical

$0.53−$0.29

-35.4%

NASDAQ · Mkt cap $4.6 M

Vision Marine announced a corporate governance update and special shareholder meeting, but the filing details remain sparse in available headlines, making it difficult to pinpoint the exact cause of the 35% single-day drop without full disclosure review.

The only news headline provided is a corporate governance announcement regarding a special shareholder meeting, with materials filed on 2026-07-30. The headline is truncated and does not specify the substance of the governance changes or the purpose of the meeting. A 35% single-day drop in a micro-cap stock like Vision Marine (trading at $0.53) could theoretically stem from shareholder dilution concerns, management changes, financial restatement, going-concern warnings, or activist pressure—all topics that might surface in a special meeting notice. However, the headline itself provides no concrete detail to confirm any of these. Without access to the full proxy filing or press release text, this remains inference territory. Micro-cap stocks are also highly volatile and can react to technical factors, short covering, or market-wide liquidity events independent of news.

MGRX

Mangoceuticals, Inc. - Common StockHealthcare

$0.56−$0.22

-31.5%

NASDAQ · Mkt cap $7.2 M

Mangoceuticals announced a business combination with Nuclea Energy on July 30, transforming itself from a mango supplement company into a nuclear microreactor vehicle, which likely triggered a sharp selloff from existing shareholders unhappy with the pivot.

The headlines establish that Mangoceuticals signed a definitive agreement to merge with Nuclea Energy, a lead-cooled microreactor developer, positioning the combined entity as a Nasdaq-listed nuclear technology company. This is a fundamental business transformation, not an incremental corporate action. Existing Mangoceuticals shareholders faced with a complete pivot from consumer supplements to advanced nuclear technology—and the dilution and risk profile that accompanies a SPAC-like combination—typically exit positions rapidly. The 31.5% single-day drop reflects panic selling and likely disappointment among holders who owned the stock for its original business model or valuation. The merger itself may be strategically sound given AI-driven power demand, but that rationale does not override the immediate negative price action caused by unexpected business model extinction.

HOWL

Werewolf Therapeutics, Inc.Healthcare

$0.35−$0.15

-29.4%

NASDAQ · Mkt cap $20 M

Werewolf Therapeutics reported Q2 2026 financial results on July 31st, likely disappointing investors with clinical or financial metrics that triggered a sharp 29.4% sell-off in this early-stage biotech stock.

The company released second quarter 2026 financial results and corporate updates on the same day as the stock's decline, which is the most direct temporal link to the move. However, the provided headline is truncated and does not include the actual financial figures, clinical trial outcomes, cash position, or any forward guidance that would explain investor reaction. For early-stage biopharmaceutical companies like Werewolf Therapeutics, stock price volatility is typically driven by clinical trial data, cash runway disclosures, partnership announcements, or changes in development timelines. Without access to the full earnings release details, we cannot confirm whether the sell-off was triggered by disappointing efficacy data, a cash burn rate concern, a delayed clinical milestone, loss of a key partnership, or simply a guidance reduction. The magnitude of the decline suggests material negative news rather than minor operational updates.

SBEV

Splash Beverage Group, Inc.Consumer Defensive

$0.37−$0.17

-29.2%

NYSE · Mkt cap $2.5 M

Splash Beverage Group fell 29% on July 31 with no news headlines in the prior 48 hours, leaving the specific catalyst unclear but pointing toward either a delayed announcement, technical selling, or market rumor.

The absence of any news headlines in the last 48 hours makes it difficult to pinpoint a concrete trigger for the 29% single-day decline. For a micro-cap beverage company trading at $0.37, possible catalysts typically include dilutive equity raises, disappointing earnings or guidance, loss of a major distributor or retail partner, executive departures, regulatory actions, or missed debt covenants. The stock's position as the 16th biggest loser of the day suggests broad selling pressure rather than an isolated technical glitch. Without headlines, the move could reflect delayed disclosure of material news, a private placement announcement, or market chatter that has not yet reached major news wires. Beverage stocks are sensitive to volume trends, retail partnerships, and cash position updates.

SDST

Stardust Power Inc.Industrials

$0.53−$0.21

-28.3%

NASDAQ · Mkt cap $8.6 M

No news headlines were reported in the last 48 hours for Stardust Power Inc., so the 28.35% single-day drop cannot be directly attributed to a disclosed catalyst. The decline likely reflects technical selling, a delayed announcement, or market-wide pressure on this micro-cap stock.

The absence of any Yahoo Finance headlines in the last 48 hours is notable given the severity of the move, ranking SDST as the 17th biggest loser on the day. This suggests either that the triggering event has not yet been reported by major news aggregators, or the decline was driven by non-news factors. For a stock trading at $0.53 on NASDAQ, common causes of large single-day drops without immediate news coverage include technical capitulation or stop-loss cascades, gaps between news releases and indexer pickup, private company developments not yet publicly disclosed, or sector-wide weakness in renewable or power infrastructure stocks. Without specific headlines or structural context about SDST's capital structure or recent trading dynamics, the catalyst remains unidentified.

YYAI

Connexa Sports Technologies Inc.Technology

$0.12−$0.05

-28.1%

NASDAQ · Mkt cap $3.9 M

AiRWA Inc. (trading as YYAI) announced completion of its acquisition of Hong Kong Best Life Trade Co., which likely disappointed investors expecting stronger strategic details or growth catalysts from the deal.

The headline confirms that AiRWA completed its previously announced acquisition of Best Life on July 30, 2026, triggering the 28% single-day drop on July 31. While acquisition completions are typically neutral to positive events, the market reaction suggests investor disappointment. Possible explanations include: the deal terms being viewed as unfavorable, the acquisition offering limited synergy or growth upside relative to price paid, concerns about integration risk or Hong Kong exposure, or the announcement coinciding with broader portfolio rebalancing by holders. The snippet provided is incomplete and lacks financial details, deal rationale, or management commentary that would clarify investor sentiment. Without full earnings accretion analysis or strategic positioning details, we cannot determine whether the market is pricing in dilution, overpayment, or execution risk.

GLUE

Monte Rosa Therapeutics, Inc.Healthcare

$16.53−$6.17

-27.2%

CERS

Cerus CorpHealthcare

$2.15−$0.74

-25.5%

IMPX

AEA-Bridges Impact Corp.

$1.81−$0.62

-25.5%

VCYT

Veracyte IncHealthcare

$46.20−$13.66

-22.8%

NASDAQ · Mkt cap $3.6 B

Veracyte beat Q2 earnings and raised 2026 guidance, yet the stock fell 22.8% regardless, suggesting the market viewed the results or forward outlook as insufficient to justify current valuation despite positive headline metrics.

The headlines establish that Veracyte delivered a strong earnings beat, with revenue surpassing estimates by 4.13% and earnings beating by 25.58%, while raising full-year 2026 revenue guidance to $590-596 million. The company also reported 15% revenue growth and launched new strategic products. Under normal circumstances, this would support a rally. The sharp decline despite positive fundamentals suggests a valuation reset: the stock may have been priced for even more aggressive growth, or the market has reassessed the company's long-term margin profile, competitive position, or total addressable market. The headline "Is Veracyte Fully Valued After Raising 2026 Revenue Guidance?" directly signals this tension. Without access to the earnings call transcript or analyst commentary on margin guidance, capital allocation plans, or competitive pressures, the precise reason for the downward repricing is not fully transparent from these headlines alone.

MYSEW

MYSEWTechnology

$0.04−$0.01

-22.6%

NASDAQ

No news headlines were found in the last 48 hours, so the 22.61% decline cannot be attributed to a specific announced event. The drop likely reflects either technical selling pressure, delayed news impact, or broader market conditions affecting this micro-cap stock.

The absence of recent headlines means we cannot tie this decline to a concrete catalyst such as earnings results, regulatory action, or guidance changes. MYSEW is trading at $0.04, indicating it is an extremely low-priced security, typically characteristic of micro-cap or penny stocks that experience higher volatility and are more susceptible to momentum-driven moves, technical chart breaks, or retail trading activity. Without news context, the decline could reflect profit-taking after a prior run-up, liquidation pressure, or a rumor not yet captured in formal news channels. Alternatively, the decline may stem from a news event that occurred more than 48 hours ago but is only now being reflected in price action, or from a non-public development known to insiders or market participants ahead of official disclosure.

DGNX

DIGINEX LIMITEDIndustrials

$1.52−$0.40

-22.3%

NASDAQ · Mkt cap $37 M

Diginex rebounded to Nasdaq compliance on July 30, but the stock still fell 22.35% by July 31, suggesting the compliance news was insufficient to restore investor confidence or other negative factors emerged after the announcement.

The only headline provided announces that Diginex regained compliance with Nasdaq's minimum bid price requirement on July 30. This is ostensibly positive news, as it removes the threat of delisting. However, the stock dropped sharply the next day, which indicates the market either viewed the compliance restoration as insufficient to address underlying concerns, or that additional negative information emerged between the announcement and market close on July 31 that is not captured in the provided headlines. The company is described as an ESG and compliance solutions provider, but no details about earnings, guidance changes, contract losses, or other operational developments appear in the available news. The disconnect between the positive compliance announcement and the large same-day or next-day decline suggests either technical selling pressure unrelated to fundamentals or undisclosed negative catalysts not reflected in the Yahoo Finance RSS feed provided.

ADVB

Advanced Biomed Inc. Common StockHealthcare

$8.10−$2.26

-21.8%

NASDAQ · Mkt cap $14 M

No news headlines were published in the last 48 hours on ADVB, so the 21.81% drop cannot be linked to a specific announced catalyst; the move likely reflects either a delayed market reaction to earlier news, a sector-wide downturn, or company-specific developments not yet captured in headlines.

The absence of recent news is notable given the magnitude of the decline. A biomedical company experiencing a one-day loss of nearly 22% typically moves on material events such as clinical trial results, regulatory setbacks, earnings misses, analyst downgrades, or guidance cuts. Since no such headlines appear in the 48-hour window, several scenarios are plausible: first, the catalyst may have been announced more than 48 hours ago and the market is still repricing; second, negative news or rumors may have circulated through investor channels before formal disclosure; third, a broader healthcare or biotech sector decline may have dragged ADVB down; or fourth, an unexpected after-hours announcement or earnings report timed just outside the headline capture window could explain the move. Without access to the company's recent filings, regulatory filings, or intraday news flow, pinpointing the exact driver is not possible from available evidence.

PWCM

PowerCompute, Inc.Financial Services

$2.15−$0.41

-21.5%

NASDAQ · Mkt cap $1.5 M

No news headlines were found in the last 48 hours for PWCM, so the 21.47% single-day drop cannot be attributed to a specific announced event; the cause likely falls into technical selling, delayed news pickup, or undisclosed corporate developments.

The absence of recent Yahoo Finance headlines makes it impossible to pinpoint a concrete catalyst for the sharp decline. PowerCompute is a small-cap Nasdaq stock (trading at $2.15), and stocks in this category can experience volatile single-day moves for several reasons even without immediate news coverage. The most common causes would be: first, a delayed announcement that has not yet been picked up by major news aggregators but was disclosed via regulatory filing or company press release; second, technical selling triggered by breaking below a key support level or stop-loss orders; or third, sector-wide pressure or a short report released outside of traditional news channels. Without corroborating information, any explanation remains speculative. It is also possible that the news has not yet propagated to the RSS feed snapshot being reviewed.

RDDT

Reddit, Inc.Communication Services

$140.67−$37.36

-21.0%

NYSE · Mkt cap $30 B

Reddit plunged 21% despite beating Q2 earnings and raising guidance, driven by CEO warnings of volatile and choppy search referrals and slowing U.S. user growth, which sparked fears about AI-driven traffic disruption threatening the ad-dependent business model.

Reddit reported strong Q2 results with record revenue and ad growth, beating analyst expectations and providing upbeat forward guidance. However, the stock cratered because CEO Steve Huffman warned of volatile search referrals and weaker domestic user expansion, signaling unpredictable traffic patterns and growth headwinds. The headlines reveal investor concern that AI-powered search engines and data scrapers are redirecting traffic away from Reddit, undermining the platform's value despite current monetization strength. The fact that Alphabet surged on the same day while Reddit collapsed underscores the market's fear that generative AI is a structural threat to Reddit's search-dependent traffic model. Multiple analysts framed this as an earnings beat overshadowed by forward-looking AI and traffic concerns rather than backward-looking earnings disappointment. This represents a classic case where near-term financial performance is discounted heavily due to existential medium-term business model risk.

EVTV

Envirotech Vehicles, Inc.Technology

$1.43−$0.38

-20.8%

TRUG

TruGolf, Inc.Consumer Cyclical

$0.85−$0.22

-20.6%

NASDAQ · Mkt cap $1.2 M

No news headlines were found in the last 48 hours, so the 20.55% drop cannot be directly attributed to a public announcement. The decline may reflect technical selling, retail trading volatility, or undisclosed developments in a micro-cap stock.

TruGolf trades on NASDAQ as a micro-cap equity with a current price near $0.85. The absence of any news in the Yahoo Finance RSS feed over the past two days means no earnings report, product announcement, regulatory action, or corporate event can be directly linked to today's sharp decline. Stocks in this price range and market cap tier are often subject to higher volatility and can be driven by several factors: technical breakdown below key support levels, liquidation by small holders, shifts in trader sentiment on social platforms, or delayed reporting of material events that may not immediately surface in major news feeds. Without access to SEC filings, company press releases, or social media signals, the specific catalyst remains opaque.

ALHC

Alignment Healthcare, Inc.Healthcare

$14.85−$3.76

-20.2%

NASDAQ · Mkt cap $2.8 B

Alignment Healthcare beat Q2 earnings and revenue estimates and raised full-year guidance, yet the stock plunged 20%, suggesting the market either priced in stronger results or has concerns about the profitability and execution risk of planned second-half investments despite the guidance raise.

The earnings headlines present a paradox: ALHC delivered a +30.77% earnings surprise, +1.97% revenue surprise, 31% membership growth, 32% revenue increase, and raised full-year guidance across multiple metrics. By conventional standards, this would support a rally. However, a 20% drop on strong results typically reflects one of several dynamics: (1) the guidance raise may have disappointed relative to whispered expectations or internal investor models, (2) the company signaled material planned investments in the second half that create near-term margin or cash flow concerns despite long-term optimism, (3) the market is repricing the valuation upward at a rate slower than the growth rate, or (4) institutional holders are taking profits after a prior run-up. The headlines mention the company is raising guidance "despite planned second-half investments," which flags a potential profitability headwind that may have overshadowed the beat in investor sentiment.

AMPGZ

Amplitech Group, Inc. Series B Right

$0.60−$0.15

-20.0%

NASDAQ

No news headlines were published in the last 48 hours; the 20% decline in this Series B right offering is likely driven by movement in the underlying Amplitech common stock, technical selling, or broad market conditions affecting penny-range securities.

No recent news headlines are available to explain the move in AMPGZ, a Series B rights offering that tracks or derives value from Amplitech Group's equity. Rights offerings are derivative securities whose value is typically tied to the underlying common stock price and exercise terms. A 20% single-day decline in a sub-$1 security with no published catalogs could reflect several mechanisms: weakness in Amplitech's common stock, deterioration in the in-the-money value of the rights, technical selling pressure common in low-float penny stocks, or broader market headwinds. Without access to intraday moves in AMPLI (the parent common) or any corporate announcement, earnings release, or guidance change, the specific trigger remains unidentified. The absence of news in Yahoo Finance's RSS feed does not rule out a company-specific event; it may indicate limited analyst coverage or delayed news propagation for microcap securities.

RFAMR

RF Acquisition Corp III Rights

$0.12−$0.03

-20.0%

NASDAQ

No news headlines were found in the last 48 hours, so the 20% drop in RF Acquisition Corp III Rights likely reflects typical volatility in SPAC rights instruments or broader market factors affecting blank-check vehicles.

RF Acquisition Corp III Rights is a SPAC rights offering, a derivative security tied to the parent SPAC's fortunes. The absence of any news in the last 48 hours means we cannot point to a company-specific catalyst such as a merger announcement delay, deal termination, or governance change. Rights offerings are inherently volatile instruments with low trading volume and wide bid-ask spreads, making them prone to sharp percentage moves on modest share volume. The drop could stem from several categories of cause: broader weakness in the SPAC sector, technical selling or profit-taking, liquidity events, or changes in expectations about the underlying SPAC's transaction prospects. Without headlines or volume data, attribution is speculative. Structural characteristics of rights—leverage, illiquidity, and dependence on the parent vehicle's momentum—make them naturally volatile, especially around critical SPAC milestones like merger deadlines or shareholder votes.

Skycorp Solar Group Limited Ordinary SharesEnergy

$17.09−$3.79

-19.2%

NASDAQ · Mkt cap $5.4 M

PN Smart Energy announced completion of its acquisition of Nanjing Cesun Power on July 30, a major strategic move toward becoming an independent power producer, yet the stock fell 19.15% the next day, suggesting investor skepticism about deal terms, execution risk, or valuation dilution despite t…

The only headline provided is PN Smart Energy's announcement of completing its acquisition of Nanjing Cesun Power, framed as advancing the company's transition to an independent power producer. Typically, acquisition completions are received positively if terms are favorable or perceived as strategically sound, but a 19% drop the following day indicates the market may be concerned about several factors: the deal structure or terms may involve dilution to existing shareholders, debt assumptions or balance sheet strain, overpayment relative to asset quality, execution risks integrating the acquired power operations, or broader market skepticism about the IPP business model or China-based operations. Without details on purchase price, financing method, or operational metrics, the exact source of the selloff cannot be determined from the headline alone. The magnitude of the decline suggests this was not a minor technical reaction but a material reassessment of company value.

HUN

Huntsman CorpBasic Materials

$9.76−$2.31

-19.1%

NYSE · Mkt cap $1.6 B

Huntsman reported break-even Q2 earnings (missing estimates by 100%) and guided for only stable conditions ahead, citing subdued demand and weak housing indicators, triggering the sharp 19% sell-off.

Huntsman released Q2 results on July 30th showing a net loss of $6 million with zero adjusted net income, missing analyst expectations entirely (negative 100% earnings surprise). While revenue beat modestly at $1,663 million versus estimates, the bottom-line miss and lack of profitability disappointed the market. The earnings call added pressure by highlighting subdued demand growth and weaker North American housing indicators, with management guiding only for relatively stable Q3 conditions rather than improvement. The company did maintain its dividend at $0.0875 per share, suggesting confidence in cash flow, but investors appear focused on the demand weakness and profitability concerns rather than reassured by the dividend. The combination of earnings miss, weak forward guidance tied to housing and demand headwinds, and exposure to cyclical end-markets likely triggered the substantial sell-off.

MTZ

MasTec IncFinancial Services

$263.00−$61.53

-19.0%

NYSE · Mkt cap $17 B

MasTec posted record revenue growth of 23% and raised full-year 2026 guidance with surging EBITDA, yet the stock fell 19% anyway, likely due to a narrowly missed EPS target and investor sentiment that the rally was already priced in.

MasTec delivered objectively strong Q2 results: revenue beat estimates by 1.81%, EBITDA surged 40%, and the company raised full-year guidance citing unprecedented demand across power, pipeline, and clean energy. However, the company missed non-GAAP EPS by approximately 0.6%, and multiple headlines suggest the market viewed the strong report as fully reflected in valuation already. One analyst piece directly questioned whether MTZ was "fully priced" as guidance landed. The Mizuho commentary that "it doesn't matter how good earnings or guidance is for many companies" in the current environment suggests broader market sentiment against infrastructure and construction stocks despite solid fundamentals. The 19% drop despite operational strength points to valuation concerns and sector rotation rather than business deterioration.

NXTC

NextCure IncHealthcare

$4.10−$0.95

-18.8%

NASDAQ · Mkt cap $31 M

No news was published in the last 48 hours to explain NextCure's 18.81% drop, suggesting the decline may be driven by clinical trial results, earnings disappointment, insider activity, or broader biotech sector weakness that has not yet appeared in the RSS feed.

The absence of any headlines in the last 48 hours surrounding an 18.81% single-day decline for a biotech stock like NextCure is notable and unusual for a move of this magnitude. NextCure is a clinical-stage immunotherapy company, and stocks in this category are typically highly sensitive to developments in trial outcomes, regulatory actions, funding announcements, or cash-burn milestones. The lack of captured news could reflect several scenarios: a major announcement or trial result may have broken outside the Yahoo Finance RSS window, company insiders may have transacted, short-seller activity or a short report may have circulated, or the broader biotech sector may have experienced a significant sell-off not yet reflected in company-specific headlines. Without access to real-time market news, earnings calendars, or SEC filings from the snapshot date, the exact trigger remains unclear.

WLDS

Wearable Devices LtdTechnology

$2.55−$0.58

-18.4%

NASDAQ · Mkt cap $6.0 M

Wearable Devices announced a $3.3 million private placement at-the-market pricing, which typically triggers shareholder dilution concerns and often causes stock declines on capital raises by micro-cap growth companies.

The headline confirms Wearable Devices disclosed a private placement of $3.3 million priced at-the-market under Nasdaq rules with a single institutional investor on July 31, 2026. Private placements, especially at-the-market offerings by small-cap companies, commonly pressure stock prices due to dilution of existing shareholders and the signal that management may be raising capital at depressed valuations. The timing of the announcement matching the exact snapshot date and the magnitude of the single-day decline of 18.4% are consistent with market reaction to announced dilution. However, the full press release is truncated in the provided text, so details about the terms, use of proceeds, and the investor's identity are not available. These factors could have modulated investor response.

BTSG

BRIGHTSPRING HEALTH SERVICES INCHealthcare

$59.67−$13.11

-18.0%

NASDAQ · Mkt cap $12 B

BrightSpring beat earnings estimates and raised full-year guidance on strong growth, yet the stock plunged 18% the same day, suggesting the market either anticipated even stronger results, worried about IRA headwinds overshadowing the beat, or reacted to forward guidance that disappointed despite…

The headlines establish that on July 31, 2026, BrightSpring reported a 21.62% earnings beat and 6.11% revenue beat for Q2, with revenue surging 23% year-over-year and management raising full-year 2026 guidance. Ordinarily such results would support a stock rally. However, the 18% same-day decline suggests the market either priced in an even larger beat beforehand, or found the guidance raise insufficient relative to expectations. The earnings call highlights note IRA headwinds as a drag despite strong Pharmacy Solutions and Provider Services growth. This mixed message—strong operational performance offset by regulatory/reimbursement pressure—may have spooked investors who feared margin compression or that guidance upside was limited. Without access to management commentary on margin trends, forward earnings revisions by analysts, or client/sell-side reaction, we cannot definitively isolate which aspect disappointed the market.

FLGT

Fulgent Genetics IncHealthcare

$16.57−$3.64

-18.0%

NASDAQ · Mkt cap $541 M

Fulgent Genetics fell 18% after reporting Q2 earnings that missed revenue estimates by 9.16% and posted a net loss, despite 4% year-over-year revenue growth to $85.4 million.

The company released second-quarter 2026 results on July 30 that triggered the sharp decline. The headlines establish that Fulgent missed revenue expectations by 9.16% and delivered a negative earnings surprise of 26.09%, reporting a net loss for the quarter. While the company did achieve 20% sequential growth and 4% year-over-year growth to $85.4 million revenue, incorporating a full quarter from the Bako Diagnostics acquisition, the profitability miss and below-consensus revenue appear to have overshadowed these positives. One headline also mentions billing system transition challenges, which may indicate operational friction affecting margins or revenue recognition timing. The news references strategic progress in clinical pipeline and AI diagnostics expansion, but these forward-looking initiatives did not offset investor disappointment with actual quarterly results and likely revised guidance expectations.

PRM

Perimeter Solutions, SABasic Materials

$30.60−$6.65

-17.9%

NYSE · Mkt cap $5.2 B

Perimeter Solutions crashed 17.85% despite reporting record adjusted EBITDA of $105.6 million, driven by a significant earnings miss of -18.61% and a $181.6 million net loss that overshadowed operational progress.

The earnings release on July 31 reveals a paradoxical result: while adjusted EBITDA hit record levels at $105.6 million with strong Specialty Products revenue growth and the Monocle acquisition contributing positively, the headline GAAP net loss of $181.6 million and diluted loss per share of $1.11 badly missed consensus estimates by 18.61%. This large gap between adjusted metrics and reported losses suggests significant non-cash charges, restructuring costs, or acquisition-related write-downs that investors punished severely. The -2.95% revenue miss compounds the disappointment. Market participants appear to have prioritized the bottom-line GAAP loss over management's adjusted EBITDA narrative, treating the divergence as a red flag rather than a temporary accounting phenomenon.

EZRA

Reliance Global Group, Inc.Financial Services

$1.80−$0.38

-17.7%

NASDAQ · Mkt cap $2.0 M

Reliance Global Group reported Q2 2026 earnings and announced an AI-driven transformation on July 30, but the headline provided is truncated and does not disclose specific results, guidance, or forward-looking statements that would explain the 17.73% single-day drop.

The company announced Q2 2026 results and emphasized its proprietary AI platform for insurance operations on July 30 at 4:30 PM Eastern Time. However, the news snippet is incomplete and does not include actual earnings figures, revenue trends, profit margins, subscriber losses, guidance cuts, or management commentary that typically drive large intraday declines. The announcement frames AI transformation positively, which on its face would not support a sharp selloff. Without access to the full earnings release or conference call details, possible drivers could include disappointing revenue or earnings misses relative to consensus, negative guidance revisions, margin compression in core insurance operations, or unfavorable Q3/forward-year outlook statements made during the call. Market reaction to AI announcements in mature insurance businesses is mixed and depends heavily on profitability and execution credibility.

Western Union Co-TheFinancial Services

$6.36−$1.33

-17.3%

NYSE · Mkt cap $2.3 B

Western Union missed Q2 earnings expectations by 27.91%, reported flat year-on-year revenue of $1.01 billion, cut full-year guidance to 3-5% growth, and reported adjusted EPS of $0.31 versus consensus of $0.42, driving the 17.25% stock decline.

The earnings miss was substantial and multifaceted. Headline earnings surprised to the downside by nearly 28 percent while revenue essentially met expectations, signaling margin compression and cost pressures. Management cited slower-than-expected acquisition synergies and ongoing retail declines as headwinds. The full-year guidance cut to 3-5% revenue growth represents a material reduction in prior outlook. While the company noted positive developments including 25% growth in branded digital transactions and a new stablecoin launch, these positives were overwhelmed by the earnings shortfall, margin pressure, and reduced forward guidance. The combination of a missed quarter, lowered full-year expectations, and structural headwinds in retail money transfer operations created a clear catalyst for the sharp sell-off.

BIYA

Baiya International Group Inc. Ordinary SharesTechnology

$3.35−$0.67

-17.0%

NASDAQ · Mkt cap $71 M

No news headlines were reported in the last 48 hours for BIYA, so the 17% drop on July 31, 2026 cannot be directly attributed to a company-specific announcement or event based on available information.

The absence of recent news headlines makes it difficult to pinpoint a specific catalyst for BIYA's 17% single-day decline. However, small-cap stocks trading on NASDAQ like BIYA are commonly subject to moves driven by several categories of events that may not immediately surface in major financial news feeds: delayed regulatory filings or compliance issues, after-hours or pre-market announcements by the company itself, sector-wide selloffs affecting similar-sized companies, changes in analyst coverage or ratings, or shifts in insider trading activity. Additionally, illiquid or thinly traded small-cap stocks can experience sharp moves on relatively modest trading volume, sometimes driven by technical factors or algorithmic trading rather than fundamental news. Without access to company filings, insider transactions, or real-time trading data, the specific driver remains unknown.

KSCP

Knightscope, Inc.Industrials

$1.65−$0.34

-17.0%

NASDAQ · Mkt cap $26 M

Knightscope announced its Q2 2026 earnings call but provided no results or guidance in the headline, leaving investors uncertain about performance; the 17% drop likely reflects pre-earnings anxiety or negative expectations rather than disclosed bad news.

The only news provided is a bare announcement that Knightscope will hold an earnings call to discuss Q2 results. No actual earnings data, guidance, or performance metrics are disclosed in the headline. A 17% single-day drop on just a call announcement is unusual and suggests either the market had expected results to already be public, investors are pricing in anticipated weak performance ahead of the call, or there is other negative information not captured in this headline feed. For a small-cap security technology company, typical drivers of sharp moves include disappointing unit sales, cash burn updates, contract losses, or revised guidance. Without the actual earnings release or management commentary in the provided headlines, the specific trigger remains unclear, though the timing around the call suggests earnings-related uncertainty is the most probable category.

VSME

VS Media Holdings Limited - Class A Ordinary SharesCommunication Services

$1.30−$0.25

-17.0%

RITR

Reitar Logtech Holdings Limited Ordinary sharesIndustrials

$0.06−$0.01

-16.7%

NASDAQ · Mkt cap $4.8 M

No news headlines were found in the last 48 hours to explain RITR's 16.72% drop on July 31, 2026, making the specific cause unclear without additional reporting or company filings.

The absence of recent news headlines means we cannot point to a specific catalyst such as earnings disappointment, a guidance cut, regulatory action, or corporate event. RITR is a micro-cap stock trading at $0.06, which typically exhibits high volatility and can move sharply on minimal volume or sentiment shifts. Possible categories of explanation include technical selling pressure from existing holders, a delayed announcement not yet picked up by major news feeds, insider trading activity disclosed in filings, short-seller reports or social media commentary, broader market pressure on low-priced equities, or a rumor in less-reported channels. Without access to current SEC filings, level-2 data, or industry coverage beyond the provided sources, it is impossible to distinguish between these hypotheses. The stock's rank as the 46th biggest loser suggests the move was material but not unprecedented for a nano-cap equity.

GDDY

GoDaddy IncTechnology

$82.77−$16.57

-16.7%

NYSE · Mkt cap $13 B

GoDaddy's stock plunged 16.68% following a disappointing full-year revenue outlook announced alongside Q2 earnings, despite beating quarterly estimates, due to slower AI adoption and weaker customer acquisition.

GoDaddy reported Q2 earnings and revenue that exceeded Wall Street estimates with 7% year-over-year revenue growth and strong Airo (AI product) adoption surging to $50M ARR. However, the company simultaneously narrowed its full-year revenue forecast, which triggered the sharp sell-off. The disconnect between quarterly beats and forward guidance cuts reveals investor concern about the sustainability of growth. Management attributed the guidance reduction to slower than expected adoption of AI tools company-wide and weaker customer acquisition trends. This suggests that while Airo shows promise, the broader business is facing headwinds that offset near-term strength, causing markets to reprrice growth expectations downward despite the solid Q2 results.

AZIO

Azio AI Holdings, Inc.Technology

$1.44−$0.28

-16.7%

NASDAQ · Mkt cap $23 M

AZIO announced a major fiber interconnectivity agreement with AT&T for its first 500MW AI data campus on July 31st, yet the stock fell 16.67%, suggesting investors may have viewed the deal terms as unfavorable, dilutive to near-term economics, or insufficient relative to existing expectations.

The headline reports a material partnership with AT&T covering fiber infrastructure for AZIO's flagship AI data center campus, which would typically be viewed as a positive catalyst for a data center infrastructure company. However, the substantial same-day decline indicates the market likely focused on unfavorable details not disclosed in the headline snippet provided. Possible explanations include concerns over: financial terms or revenue sharing that disadvantage AZIO, capacity constraints or delays implied by the specific 500MW scale, dilution or capital requirements to fund the buildout, or misalignment between the announcement timing and investor expectations for a larger or more lucrative deal. Without access to the full press release, investor call, or analyst reaction, the precise reason for the negative reception remains unclear, though the timing and magnitude suggest fundamentals or deal structure rather than pure sentiment.

NWAX.WT

New America Acquisition I Corp. WT

$0.40−$0.08

-16.7%

OLN

Olin CorpBasic Materials

$18.51−$3.67

-16.5%

NYSE · Mkt cap $1.9 B

Olin reported Q2 earnings that matched estimates with flat EPS surprise but faced headwinds from geopolitical volatility and a VCM outage, while the company navigates an ongoing Huntsman merger and cost-cutting initiatives that appear insufficient to offset near-term operational challenges.

Olin announced Q2 2026 results on July 30-31, matching earnings estimates (0.00% surprise) while delivering a modest revenue beat of 1.30%. However, the company posted a net loss of $13.3 million versus profitability in the year-ago quarter, a material deterioration that likely triggered the sell-off. The earnings call highlights cite specific operational drags: geopolitical volatility and a VCM (vinyl chloride monomer) outage impacting results. While management is advancing merger synergies with Huntsman and executing the Beyond 250 cost-cutting program, these forward-looking initiatives appear to offer limited reassurance to investors focused on current-quarter weakness. The miss on profitability despite beating revenue suggests margin compression, which is especially concerning for a chemical manufacturer facing input cost or demand pressures.